Hearscape
← Therapeutics
Details checkedStatus confirmedHistorical/discontinuedCheckedtrial

AM-101 by Auris Medical and Altamira

Also known as: AM-101, Keyzilen, esketamine gel

Altamira Therapeutics

Primary source
Company
Altamira Therapeutics
Program Type
Therapeutic
Modality
Small Molecule
Stage
Phase 3
Status
Discontinued
Target Gene
—
Route / Mode
Intratympanic injection
Confidence
93%
Status Confidence
Status confirmed
Evidence Strength
Needs more support
Last Reviewed
2026-05-31
Geography
Europe, United States
Population
adult, tinnitus
Trial IDs
6
Mechanism

Intratympanic NMDA receptor antagonist gel was designed to treat acute inner-ear tinnitus after cochlear injury.

Indications
Tinnitus
Notes

One of the best-known acute tinnitus drug programs; after repeated late-stage failures it remained a legacy Altamira inner-ear asset rather than an active development priority.

Evidence & Sources
3 structured sources
company
Supports: canonicalName, aliases, indications, notes
IDs: AM-101, Keyzilen
Open
clinicaltrials
Supports: trialIds, stage, route
IDs: NCT02040194
Open
company
Supports: company, allCompanies, status
IDs: AM-101, Keyzilen
Open
Key Events
2016-08-18
Auris reported negative TACTT2 top-line results for Keyzilen
Clinical Trials (6)
NCT02040194NCT01934010NCT02040207NCT00860808NCT01270282NCT01803646
Related Programs
PEDMARK by Fennec Pharmaceuticals
Company: Fennec Pharmaceuticals · Small Molecule · Marketed
SENS-401 (Arazasetron) by Sensorion
Company: Sensorion · Small Molecule · Phase 2
AC102 by AudioCure Pharma
Company: AudioCure Pharma · Small Molecule · Phase 2
SPI-1005 by Sound Pharmaceuticals
Company: Sound Pharmaceuticals · Small Molecule · Phase 3
ACOU085 by Acousia Therapeutics
Company: Acousia Therapeutics GmbH · Small Molecule · Phase 2
CIL001 (Paliroden) by Cilcare
Company: Cilcare SAS · Small Molecule · Phase 1/2